Natera’s Strong Q1 2025 Performance and Strategic Growth Justify Buy Rating

Canaccord Genuity analyst Kyle Mikson CFA maintained a Buy rating on Natera (NTRA – Research Report) yesterday and set a price target of $195.00.

Kyle Mikson CFA has given his Buy rating due to a combination of factors that highlight Natera’s strong performance and future potential. The company reported first-quarter results for 2025 that surpassed both the analyst’s and market expectations, driven by significant growth in test volumes across its business segments. This growth was further supported by an increase in average selling prices and strategic one-time adjustments.
Natera is also making strides in gaining approval for its Signatera test in Japan, which is expected to enhance its market presence internationally. The company has raised its revenue guidance for 2025, reflecting confidence in its growth trajectory. Additionally, Natera’s ongoing data generation and international expansion efforts are expected to solidify its leadership in the minimal residual disease testing market. The stock is considered undervalued, with an attractive upside potential, justifying the Buy rating.

In another report released today, Morgan Stanley also reiterated a Buy rating on the stock with a $185.00 price target.

Based on the recent corporate insider activity of 179 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NTRA in relation to earlier this year.